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Dysregulated metabolism is a hallmark of cancer
cell lines, but little is known about the fate of glucose
and other nutrients in tumors growing in their native
microenvironment. To study tumor metabolism
in vivo, we used an orthotopic mouse model of pri-
mary human glioblastoma (GBM). We infused
13C-labeled nutrients into mice bearing three in-
dependent GBM lines, each with a distinct set of
mutations. All three lines displayed glycolysis, as ex-
pected for aggressive tumors. They also displayed
unexpectedmetabolic complexity, oxidizing glucose
via pyruvate dehydrogenase and the citric acid cycle,
and using glucose to supply anaplerosis and other
biosynthetic activities. Comparing the tumors to sur-
rounding brain revealed obvious metabolic differ-
ences, notably the accumulation of a large glutamine
pool within the tumors. Many of these same activities
were conserved in cells cultured ex vivo from the
tumors. Thus GBM cells utilize mitochondrial glu-
cose oxidation during aggressive tumor growth
in vivo.
INTRODUCTION
Malignant transformation is driven by genetic mutations that
promote unchecked proliferation, abrogate cell death programs,Cand reprogrammetabolism (DeBerardinis et al., 2008a; Hanahan
and Weinberg, 2011). Tumor metabolism is now an area of
intense research to identify novel therapeutic targets and
biomarkers for next-generation imaging (Kurhanewicz et al.,
2011; Tennant et al., 2010). Exploring the clinical applications
of cancer metabolism requires an accurate picture of metabolic
pathways of human tumors in situ. Cell culture studies have
produced insights into how tumorigenic mutations can stimulate
a metabolic phenotype characterized by high rates of glycolysis
relative to oxidative metabolism (Ramanathan et al., 2005), and
detailed studies using isotope-tracer methods have described
the intricacies of metabolic flux in cancer cell lines grown in
culture (Forbes et al., 2006). However, caution is necessary
when extending such findings to the in vivo setting, since primary
tumor cells acquire extensive genomic and gene expression
changes when adapted to growth in culture (Lee et al., 2006;
Mehrian Shai et al., 2005) andmay lose the influence of the native
microenvironment on metabolism. The importance of this latter
issue is emphasized in recent work demonstrating roles for adja-
cent, normal cells in supporting tumor cell metabolism (Nieman
et al., 2011; Zhang et al., 2012).
Glioblastoma (GBM), the most common primary malignant
brain tumor in humans, is highly metabolically active and evades
multimodal therapy, leading to short survival times. The prevail-
ing view of GBMmetabolism is that these tumors have high rates
of glycolysis and glutaminolysis with minimal oxidation of
glucose in themitochondrial citric acid cycle (CAC). This percep-
tion is largely based on studies of glioma cell lines grown under
conditions of maximal proliferation (DeBerardinis et al., 2007;
Portais et al., 1996). Clinical targeting of metabolism in GBM
is under investigation based on the assumption that glucoseell Metabolism 15, 827–837, June 6, 2012 ª2012 Elsevier Inc. 827
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Figure 1. Human Orthotopic Tumors Established from Three
Primary Human GBMs
(A) Hematoxylin and eosin (H&E) stains, EGFR in situ hybridization (ISH) and
immunohistochemistry (IHC), and Ki67 staining of parental human GBMs and
representative mouse HOTs.
(B) MRI and 18FDG-PET of representative mouse HOTs (M-1, M-2, M-3)
derived from each parental line. Arrows indicate GBM masses in the right
hemisphere.
(C) Summary of genomic and IHC data from HOTs M-1, M-2, and M-3.
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In Vivo Analysis of Glioblastoma Metabolismoxidation is suppressed in vivo (Michelakis et al., 2010).
However, recent work on intact human brain tumors demon-
strated that their metabolism involves extensive glucose oxida-
tion in vivo (Maher et al., 2012). In that study, patients were
infused with 13C-glucose during resection of solitary brain
masses, and metabolites extracted from the tumors were
analyzed by 13C NMR spectroscopy to detect the metabolic
fates of glucose. All tumors analyzed, including high-grade
gliomas and brain metastases, demonstrated avid oxidation of
glucose by pyruvate dehydrogenase (PDH) and the CAC.
Here we studied GBM metabolism by infusing 13C-labeled
nutrients into mice bearing human GBM cells that were isolated
from freshly resected tumors and implanted directly into the
NOD-SCID mouse brain, without prior adaptation to cell culture
(referred to as human GBM orthotopic tumors, HOTs). This
model is of particular interest because of growing evidence
that GBMs are organized by a cellular hierarchy in which only
a subpopulation of cells drive tumor growth. Glioma stem cells,
or tumor initiating cells, are uniquely capable of forming tumors
when transplanted into the brains of immunocompromised
mice (Singh et al., 2004). Thus the HOT model system provides
a unique opportunity to study metabolism of the most relevant
cell types in human GBM under conditions similar to their growth
in the human brain. Our goals were two-fold: first, to identify the
metabolic fates of glucose and glutamine, the two nutrients most
rapidly consumed by GBM cell lines; and second, to identify
definitive metabolic differences between the tumor and sur-
rounding brain, reasoning that metabolic activities differentiating
these two compartments could provide targets for cancer
therapy and/or tumor-specific imaging. The data show that
HOTs derived from multiple independent human GBMs exhibit
glucose oxidation via PDH and the CAC, anaplerosis, accumula-
tion of a large glutamine pool consisting in part of glutamine
synthesized de novo from glucose, and minimal glutaminolysis.
RESULTS
Genetically Diverse, Orthotopically Transplanted
Human GBMs Avidly Consume Glucose
Tumor cells were isolated during surgical resection of human
GBMs and implanted into the putamen-caudate region of the
brains of NOD-SCID mice. After 2–3 months, the mice became
symptomatic as a result of an expanding intracranial mass.
Dissection and reimplantation of tumor cells from premorbid
mice, without adaptation to culture, enabled the tumors to be
propagated indefinitely in the mouse brain. Comparing the
genomic profile (array CGH, Nimblegen) of each of the HOTs
to the patient tumors from which they were derived revealed
that they were indistinguishable (data not shown). In addition,
HOTs retained phenotypic features of the parental tumors,
including diffuse infiltration, high mitotic (Ki67) index (Figure 1A)
and 18fluoro-2-deoxyglucose (18FDG) uptake (Figure 1B).
Formetabolic studies,wechose three lines (M-1,M-2, andM-3)
that contained mutations commonly observed in human GBM
(Figure 1C). These included genomic amplification of the epi-
dermal growth factor receptor (EGFR) gene with high levels of
EGFR protein (M-2 and M-3, Figure 1A); expression of the EGFR
variant EGFRvIII (M-2, Figure S1A); and high expression of
platelet-derived growth factor receptor-a (M-1, Figure S1A).828 Cell Metabolism 15, 827–837, June 6, 2012 ª2012 Elsevier Inc.HomozygousdeletionofPTENwasobserved inM-1.All three lines
had loss of the INK4A/ARF locus and intact p53 (data not shown).
As expected for tumors with enhanced growth factor receptors
and/or loss of PTEN, all three lines displayed constitutive activa-
tion of Akt/mTOR signaling, and M-3 also had activation of ERK
(Figure S1A).We examined the tumors for hypoxia by determining
the abundance of the a-subunits of hypoxia-inducible-factor-1
and -2 (HIF-1a andHIF-2a). A fewHOT lines contained detectable
levels of HIF-1a, but this was not a consistent feature inM-1, M-2,
or M-3, and no tumors displayed significant amounts of HIF-2a
(Figure S1B). Furthermore, histopathological analysis demon-
strated infiltrating GBM cells in close proximity to host brain
microvasculature, which maintained the normal pattern of tight-
junction-associated proteins (ZO-1, Occludin-1) and associated
pericytes (Figure S1C). These observations suggest that the
HOTsmayco-opt preexistinghost cerebrovasculature for nutrient
support, perhaps avoiding significant hypoxia.
A 13C-Glucose Infusion Method to Establish Isotopic
Steady State within Orthotopic GBM Tumors
Infusion with 13C-glucose and other isotopically labeled nutri-
ents has been used to analyze metabolism in vivo, including in
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Figure 2. Time Course for 13C-Glucose Infusions in
HOT-Bearing Mice
(A) Four mice bearing HOTs derived from the same
parental tumor were infused with [U-13C]glucose for the
indicated times. The time course shows 13C enrichment
(in %) of plasma glucose in the individual mice used in
this time course experiment. Enrichment at time 0
was assumed to be 0%. All mice received a bolus of
[U-13C]glucose over 1 min followed by a continuous
[U-13C]glucose infusion as described in Experimental
Procedures.
(B) NMR isotopomer analysis for carbons 2, 3 and 4
of glutamate and glutamine. None of these carbons
demonstrated any appreciable change in 13C labeling after
150 min of [U-13C]glucose infusion.
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In Vivo Analysis of Glioblastoma Metabolismhuman tumors (Fan et al., 2009; Landau et al., 1996; Maher et al.,
2012). In order to establish the time course of maximal 13C
enrichment and isotopic steady state in the HOTs, we infused
13C-glucose into several mice bearing tumors derived from the
same human GBM. All mice received a bolus of [U-13C]glucose
followed by a continuous infusion of up to 300 min. At the end
of each infusion, 13C enrichment was determined in plasma
glucose, and the tumor was rapidly dissected from the
surrounding brain. Metabolites extracted from the tumor were
analyzed by NMR to determine labeling patterns at each time
point. More than 50% of the plasma glucose was 13C labeled
within 60 min, and this level was maintained for the duration of
the infusion (Figure 2A). In the tumor, 13C labeling in carbons
2, 3, and 4 of glutamate and glutamine were monitored as
markers of isotopic steady state (Malloy et al., 1987). All of these
carbons were labeled within 30 min. A smooth evolution of
labeling emerged from these samples, despite the fact that
they were obtained from several different mice (Figure 2B).
This demonstrates that metabolic activity was highly conserved
among these individual tumors. There was no appreciable
change in the labeling pattern after 150 min, demonstrating
that isotopic steady state had been reached (Figure 2B). AllCell Metabolism 1subsequent experiments used a bolus followed
by a continuous infusion of 150 min.
Orthotopic GBMs Simultaneously Use
Glycolysis and Glucose Oxidation
To identify the metabolic fates of glucose within
these tumors and to compare metabolic activity
of the tumor to that of the surrounding brain
tissue, mice from each line were infused with
[1,6-13C]glucose. This tracer probes many path-
ways supplied by glucose, including glycolysis,
the CAC, and biosynthesis of amino acids (Fig-
ure 3A; see Supplemental Experimental Proce-
dures for an explanation of 13C NMR spectra).
13C NMR spectroscopy of tissue extracts from
brain and tumor revealed 13C signal in many
metabolites (Figures 3 and S2). The brain
spectra were well resolved and contained the
expected 13C labeling of metabolites ex-
changing with the CAC, including glutamate,
glutamine, aspartate, and g-aminobutryic acid(GABA) (Figures 3B, S2A, and S2C). Because pyruvate derived
from [1,6-13C]glucose via glycolysis is labeled at carbon 3 (C3),
13C-13C multiplets in CAC-related metabolites only occur when
both oxaloacetate and acetyl-CoA are 13C enriched. This occurs
when the CAC turns over (cycles) normally, as expected in the
brain. 13C-lactate was apparent in all brain samples as a result
of glycolysis (Figures 3B, S2A, and S2C).
Despite the small size of the tumor samples (average 230 mg),
the tumor spectra were well resolved with excellent signal-to-
noise ratios and extensive labeling in lactate, glutamate, and
glutamine (Figures 3C, S2B, and S2D). These spectra contained
minimal labeling in GABA, which is synthesized in a subpopula-
tion of GABAergic neurons, suggesting that the tumor fragment
was highly enriched with GBM cells. This was verified in each
HOT by histopathology and neuron-specific immunohistochem-
istry (IHC), which demonstrated >90% tumor cellularity and loss
of normal neurons (data not shown). Label in C4 of glutamate and
glutamine, observed in all three spectra, results from the activity
of pyruvate dehydrogenase (PDH) in the tumor (Figure 3A).
13C-13C multiplets were also present in glutamate and glutamine
in all three spectra (Figures 3C, S2B, and S2D), demonstrating
normal turnover of the CAC in the tumors. Furthermore, labeling5, 827–837, June 6, 2012 ª2012 Elsevier Inc. 829
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Figure 3. Metabolism of [1,6-13C]Glucose in HOTs and Surrounding Brain
(A) Illustration of [1,6-13C]glucose metabolism. Filled symbols are 13C and open symbols are 12C. The diagram shows the positions of 13C after glucose is
metabolized through glycolysis, glycine synthesis, and multiple turns of the CAC. Numbers refer to carbon positions. At the bottom, the spectra demonstrate the
appearance of the 13C NMR spectra for glutamate labeled in position 4 alone (S, singlet), or in positions 3 and 4 (D34, 3-4 doublet), as detailed in Supplemental
Experimental Procedures. Abbreviations: Glc, glucose; Glc-6-P, glucose-6-phosphate; GLY, glycine; PYR, pyruvate; LAC, lactate; Ac-CoA, acetyl-CoA; CIT,
citrate; a-KG, a-ketoglutarate; OAA, oxaloacetic acid; GLU, glutamate; GLN, glutamine; LDH, lactate dehydrogenase; PDH, pyruvate dehydrogenase; GS,
glutamine synthetase.
(B and C) Brain (B) and tumor (C) spectra from a mouse with an M-2 HOT infused with [1,6-13C]glucose. Insets are GLU and GLN C2, C3, and C4. Chemical shift
assignments are the same for all spectra in the paper: 1, NAA C2; 2, Aspartate C2; 3, Alanine C2; 4, Taurine C1; 5,Glycine C2; 6,NAAC3; 7,GABAC4; 8,Creatine
C2; 9, Aspartate C3; 10, Taurine C2; 11, GABA C2; 12 and 13, unassigned; 14, GABA C3; 15, NAA C6; 16, Lactate C3. Abbreviations: S, singlet; D, doublet; T,
triplet; Q, quartet; ppm, parts per million.
Cell Metabolism
In Vivo Analysis of Glioblastoma Metabolismin glutamine demonstrated that the tumors synthesized gluta-
mine de novo from glucose-derived glutamate. Compared to
the brain, all three tumors had much higher labeling in glutamine
relative to glutamate, with the ratio of glutamine:glutamate areas
for C2, C3, and C4measuring 1.11 ± 0.23, 1.11 ± 0.21 and 1.01 ±
0.26 in the tumors and 0.43 ± 0.02, 0.49 ± 0.04, and 0.42 ± 0.02
(mean ± SEM) in the brains. Therefore, all three HOTs have intact
pathways of glucose oxidation, and the differences in GABA,830 Cell Metabolism 15, 827–837, June 6, 2012 ª2012 Elsevier Inc.glutamine, and glutamate labeling establish that the tumors are
metabolically distinct from the brain in vivo with respect to their
handling of glucose-derived metabolites.
Two mice each bearing HOTs M1-M3 were then infused with
[U-13C]glucose (glucose labeled in all six positions with 13C). In
this scheme (Figure 4A), glucose-derived pyruvate and acetyl-
CoA are uniformly 13C labeled, so that multiplets occur during
the first CAC turn. In all mice, spectra from both the brain and
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Figure 4. Metabolism of [U-13C]Glucose in HOTs and Surrounding Brain
(A) Illustration of [U-13C]glucose metabolism. See legend to Figure 3A and Supplemental Experimental Procedures for details and abbreviations.
(B and C) Brain (B) and tumor (C) spectra from a mouse with an M-2 HOT infused with [U-13C]glucose. Insets are glutamate (GLU) and glutamine (GLN) C2,
C3, and C4.
(D) Ratio of glutamine area to glutamate area for carbons 2, 3, and 4 in tumor and surrounding brain. Data are the average and SEM for six individual mice, two for
each of the three HOT lines. Statistical analysis: Wilcoxon signed rank test. *p < 0.05.
(E) Top: Glutamine synthetase (GS) western blot in tumor (T) and surrounding brain (B) of HOT lines. Bottom: GS enzyme activity in two human brain samples
(HuB1, HuB2), three mouse brain samples (MoB1 to MoB3), and three HOTs (M-1 to M-3). MoB3 is the brain tissue surrounding tumor M-1. Data are the average
and SD for three replicates from each sample.
(F) Total GLN and GLU abundance in tumor and brain extracts (n = 9), measured by high-performance liquid chromatography. Data are the average and SD.
*p < 0.05; **p < 0.005, Student’s t test.
(G) Immunohistochemistry (IHC) scores for GS expression in a tissue microarray consisting of GBM (n = 81), low-grade (Grade II–III) gliomas (LGG, n = 37) and
oligodendrogliomas (Oligo, n = 33). Data are the average and SEM. ***p < 0.001, one-way ANOVA with Dunnett’s post hoc test.
Cell Metabolism
In Vivo Analysis of Glioblastoma Metabolismthe tumor contained prominent 4-5 doublets in glutamate
and glutamine, confirming the activity of PDH in both compart-
ments (Figures 4B,4C, and S3A–S3D). Evidence for complete
turnover of the CAC included the quartet (Q) in glutamate C4
and glutamine C4. Consistent with data from the [1,6-13C]
glucose infusion, glutamine was produced de novo from
glucose-derived glutamate in both compartments. Again, the
overall signal in glutamine relative to glutamate was higher in
the tumor than in the brain (Figure 4D). All three tumors ex-
pressed glutamine synthetase (GS), the enzyme that converts
glutamate to glutamine, and tumor tissue extracts possessedCGS enzyme activity (Figure 4E). Measuring total glutamine and
glutamate content in all mice infused with either [1,6-13C]
glucose or [U-13C]glucose (n = 9) revealed that the tumors con-
tained significantly more glutamine per gram of tissue, and
significantly less glutamate, than the brain (Figure 4F). We also
evaluated GS expression in a human tissue microarray of 150
gliomas. GS was highly expressed in GBM relative to low-grade
gliomas and oligodendrogliomas (Figure 4G), suggesting that
expression of this enzyme and the ability to synthesize gluta-
mine from glucose-derived glutamate are prominent metabolic
features of GBMs.ell Metabolism 15, 827–837, June 6, 2012 ª2012 Elsevier Inc. 831
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Figure 5. Anaplerosis in HOTs
(A) c-Myc IHC in HOT tumors.
(B) Protein abundance of c-Myc and two anaplerotic enzymes, glutaminase
(GLS), and pyruvate carboxylase (PC) in HOT tumors (T) and surrounding
brain (B).
(C) 13C NMR spectrum from an M-1 tumor infused with [3,4-13C]glucose. The
diagram illustrates that in this infusion, PC is active if C1 signal exceeds C5
signal in glutamate and glutamine. GLN5 was not definitively assigned; it is
either the indicated peak or coresonant with ASP4, both of which are smaller
than the GLN1 peak.
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In Vivo Analysis of Glioblastoma MetabolismSince the spectra included fully resolved multiplets, we used
glutamate isotopomer analysis to estimate some of the major
metabolic activities related to glucose oxidation. Assuming that
the tissue under investigation is metabolically homogeneous,
isotopomer analysis calculates specific metabolic parameters
from relative peak areas within glutamate multiplets (Malloy
et al., 1987; Sherry and Malloy, 2002). This analysis revealed
that plasma glucose was the major source of acetyl-CoA in the
tumor, consistent with the robust glucose oxidation and PDH
activity observed in this model (Figure S3E). The contribution
of glucose to acetyl-CoA in the tumors was similar to that of
the brain (Figure S3E). Anaplerosis, the process by which the
CAC generates excess intermediates for neurotransmitter
synthesis in the brain and for macromolecular synthesis during
cell growth (Owen et al., 2002), also contributed significantly to
overall tumor CAC activity in both compartments (Figure S3F).
Lack of Glutamine Catabolism in Orthotopic GBMs
We next examined potential mechanisms of anaplerosis in the
tumors. Glutamine is the major anaplerotic nutrient for many
cancer cells (DeBerardinis et al., 2007; Portais et al., 1996),
and cells with high levels of c-Myc have high rates of glutamine
catabolism and require glutamine for survival and growth in
culture (Wise et al., 2008; Yuneva et al., 2007). c-Myc regulates
levels of glutaminase (GLS), one of the enzymes that converts
glutamine to glutamate in cells that use glutamine catabolism
for anaplerosis (Gao et al., 2009). However, other tumor cells
use a glucose-dependent anaplerotic pathway that requires
pyruvate carboxylase (PC), and these cells do not need to
express GLS or catabolize glutamine (Cheng et al., 2011). Rela-
tive to the surrounding brain, HOTs M-1 and M-3 had abundant
c-Myc expression by IHC and western blot (Figures 5A and 5B).
As expected, M-1 and M-3 also expressed GLS, while M-2 did
not. However, in all cases GLS was much more abundant in
the surrounding brain than in the tumor. By contrast, PC was
expressed in all tumors at levels more comparable to the
surrounding brain (Figure 5B). Examination of the 13C spectra
from all tumors infused with [U-13C]glucose revealed the pres-
ence of a 2-3 doublet in glutamate C2, and this feature is con-
sistent with PC activity (Cheng et al., 2011). However, other path-
ways, including multiple turns of the CAC, may also produce this
doublet. To test definitively for PC activity, a mouse with a HOT
M-1 tumor was infused with [3,4-13C]glucose. Because glucose
labeled in this manner produces [1-13C]pyruvate, 13C only enters
the CAC if PC is active (Figure 5C). The resulting tumor 13C spec-
trum contained several features consistent with PC activity,
including labeling of carbons 1 and 4 in aspartate, and an excess
of label in carbon 1 relative to carbon 5 of glutamate and gluta-
mine (Figure 5C). Together, the data suggest that PC contributes
to anaplerosis in these tumors.
The accumulation of glucose-derived glutamine in all three
HOTs, coupled with PC activity, raised the question of whether
they engaged in glutamine catabolism. To address this, one
mouse from each line was infused with [U-13C]glutamine (Fig-
ures 6 and S4). Presence of [U-13C]glutamine in tumor and brain
is indicated by quartets in glutamine C2 and C4 and the triplet in
C3 (Figures 6B, 6C, and S4A–S4D). In the tumor, glutaminemulti-
plets far exceeded glutamate labeling, whereas the reverse
occurred in surrounding brain. The overall pattern revealed that832 Cell Metabolism 15, 827–837, June 6, 2012 ª2012 Elsevier Inc.blood-borne glutamine is taken up by the tumors, but not metab-
olized significantly. Interestingly, all three tumors infused with
[U-13C]glutamine also contained prominent 4-5 doublets at
glutamate C4 (Figures 6D, S4B, and S4D). These occur when
C4 and C5 but not C3 are labeled, and thus the pattern cannot
be produced from the direct conversion of [U-13C]glutamine to
[U-13C]glutamate. The data suggested that 13C-labeled glucose
or lactate entered the tumor and was oxidized. Because gluta-
mine is an excellent gluconeogenic precursor (Nurjhan et al.,
1995), we used mass spectrometry to measure 13C enrichment
in plasma glucose during [U-13C]glutamine infusions (Figure 6E).
Each mouse had a significant fraction of glucose m+3, the
expected product if pyruvate derived from [U-13C]glutamine
was converted to glucose in the liver or elsewhere (Figure 6F).
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Figure 6. HOTs Use Glucose, not Glutamine, to Supply the Citric Acid Cycle
(A) Illustration of [U-13C]glutamine metabolism. See legend to Figure 3A and Supplemental Experimental Procedures for details and abbreviations.
(B and C) Brain (B) and tumor (C) spectra from a mouse with an M-2 HOT infused with [U-13C]glutamine. Insets are glutamate (GLU) and glutamine (GLN)
C3 and C4.
(D) Expansion of GLU4 and LAC3 multiplets in three tumors infused with [U-13C]glutamine. Arrows highlight the 2-3 doublet in lactate and the 4-5 doublet in
glutamate.
(E) 13C enrichment in plasma glutamine, glucose, and lactate of mice infused with [U-13C]glutamine. Data are the average ± SD of three HOT-bearing mice.
(F) Schematic of metabolic activities occurring outside of the tumor by which [U-13C]glutamine is converted to glucose and lactate (dashed green arrows), which
are detected in the plasma. Subsequent metabolism in the tumor (black arrows) uses 13C glucose and/or lactate to supply the CAC.
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glutamine, calculated by the ratio of glucose m+3/glutamine
m+5, was 23 ± 6% (Figure 6E). Two of the plasma samples
also contained lactate m+3, which could have been produced
either through glutaminolysis or glycolysis of glutamine-derived
glucose. The 2-3 doublet at lactate C3, observed in all three
tumors (Figure 6D), also reflects metabolism of [U-13C]glutamine
in other tissues followed by delivery of 13C-glucose and/or
13C-lactate to the tumor. These observations reinforce the notion
that glucose is preferred over glutamine for oxidativemetabolism
in these tumors.
Glutamine Independence of Cells Derived from
Orthotopic GBMs
Finally, to determine whether these activities were cell autono-
mous, we isolated GBM cells from HOT M-3 and briefly cultured
them as neurospheres. Successful neurosphere isolation sup-
ports the view that theHOTs contain cancer stemcells and repre-Csent the truly malignant GBM cell type. These primary GBM cells
were highly dependent on glucose, but consistentwith the lack of
glutamine catabolism in vivo, they did not require glutamine for
survival and were able to maintain at least a low rate of growth
over 1 week of culture without any access to glutamine (Figures
7A and 7B). Two additional neurosphere cell lines derived from
other HOTs displayed similar properties (Figures 7A and 7B). All
three neurosphere lines expressed similar levels of c-Myc, PC,
and GS, but none expressed high levels of GLS (Figure S5A).
The three lines were then cultured with [U-13C]glucose, and
metabolites were analyzed by mass spectrometry to determine
isotopic enrichment. In all three lines, the CAC was highly en-
riched by glucose, with well over half of the citrate molecules in
these cells containing 13C in at least four of the six carbons (Fig-
ure 7C). Glutamate, malate, and aspartate were also highly en-
riched (Figure S5B). Glutamine was avidly produced from
glucose (Figure 7D), as it was in vivo. Thus, these neurospheres
are metabolically programmed to produce glutamine fromell Metabolism 15, 827–837, June 6, 2012 ª2012 Elsevier Inc. 833
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Figure 7. Cells from HOTs Survive and Grow without Exogenous
Glutamine
(A and B) show viability (A) and live cell number (B) in neurosphere cultures
derived from three HOTs (M-3, C419, and 133P) in medium containing both
glucose and glutamine, glutamine alone, or glucose alone. The dashed line
indicates the number of cells plated at the start of the experiment. Data are the
average ± SD of three independent cultures (**p < 0.005, Student’s t test).
(C) Mass isotopomer distribution of citrate in neurospheres cultured inmedium
with [U-13C]glucose. Data are the average ± SD of three independent cultures.
(D) Mass isotopomer distribution of glutamine in the same cells. Data are the
average ± SD of three independent cultures.
Cell Metabolism
In Vivo Analysis of Glioblastoma Metabolismglucoseand to survive andgrowwithout theneed for extracellular
glutamine.
DISCUSSION
We analyzed nutrient metabolism in a biologically accurate
mouse model of GBM. Contrary to the prevailing view of dimin-
ishedmitochondrial function in tumor cells, the data demonstrate
that oxidation in the CAC is a significant fate of glucose carbon in
these 18FDG-PET-positive tumors. The overall metabolic pheno-
type of GBM involved allocation of glucose carbon into oxidative
and nonoxidative pathways to produce both energy and macro-
molecular precursors. Thus, our finding rules out the possibility
that tumor metabolism is confined to aerobic glycolysis during
aggressive growth in vivo, in particular in GBMs with diffuse infil-
tration, which ensures access to the nutrient- and oxygen-rich
environment of the brain. Flux through PDH was intact in each
tumor analyzed and was the major source of carbon entering
the CAC, as it was in the surrounding brain. This observation is
at odds with the prevailing hypothesis that PDH is suppressed
in high-grade tumors (Michelakis et al., 2010). The differences
between metabolism of HOTs in vivo and in cancer cell lines
in vitro may reflect adaptation to long-term culture, loss of micro-
environmental factors that influence metabolism, or the fact that834 Cell Metabolism 15, 827–837, June 6, 2012 ª2012 Elsevier Inc.some metabolic hallmarks of cancer cell lines, particularly the
Warburg effect, reflect maximal rates of cell proliferation in
culture rather than malignancy per se (Deberardinis et al.,
2008b). Importantly, the HOTs studied here displayed numerous
metabolic similarities to primary human GBMs, which also use
PDH, the CAC, and GS in vivo (Maher et al., 2012).
An intriguing finding is that the three HOTs studied closely in
this work had similar metabolic features despite being derived
from independent human tumors with different driver mutations.
Although both EGFR and PTEN regulate PI3K signaling, which in
turn controls glucose metabolism in tumor cells (Elstrom et al.,
2004; Liu et al., 1998; Myers et al., 1998), the convergence of
these three HOTs onto a similar metabolic phenotype suggests
that neither EGFR gain-of-function nor PTEN loss-of-function is
necessary for robust glucose uptake and oxidation. Rather, the
relationship between genomic information and tumor metabo-
lism may reflect the tumor grade, or may depend on intricate
crosstalk among growth regulatory pathways operating in
a cell-context-specific fashion under the influence of the local
microenvironment. Examination of additional HOTswith different
patterns of signature GBM mutations, application of other
methods to investigate a broader swath of the metabolome,
and loss-of-function studies to examine the specific role of
particular signaling pathways, will be necessary to determine
the full spectrum of GBM metabolism in vivo and the precise
role of oncogenes in orchestrating metabolism in these tumors.
The comparison of 13C metabolism in the tumors and
surrounding brain demonstrated distinct metabolic profiles, the
most striking of which was a large glutamine pool in the tumors.
The tumors and tumor-derived neurospheres mimicked the
metabolism of a subset of cancer cell lines that rely on glucose
to provide carbon and anaplerotic flux to the CAC and do not
require exogenous glutamine for growth (Cheng et al., 2011). In
the normal brain, glutamine exchanges rapidly with glutamate
between neurons and astrocytes, but this cycle was markedly
perturbed within the HOTs. Based on the labeling data, it is clear
that all three HOTs synthesize glutamine like normal astrocytes,
perhaps reflecting their cellular origins. However, de novo
glutamine synthesis did not appear to be sufficient to explain
the large glutamine pools, because the HOTs did not possess
more GS enzyme activity than the surrounding brain. Glutamine
accumulation likely resulted from a combination of activities
including de novo synthesis, uptake of glutamine from the blood
supply, and perhaps a reduced rate of glutamine export relative
to normal astrocytes. The dense tumor cellularity and con-
sequential paucity of neurons in the tumor mass may have also
led to the appearance of glutamine accumulation. We speculate
that the high glutamine content within GBMs could serve as
an imaging biomarker using 18F-labeled glutamine analogs for
PET, or with high-field magnetic resonance spectroscopy, as
has been demonstrated for glycine and 2-hydroxyglutarate
(Choi et al., 2011, 2012; Qu et al., 2011).
The potential to develop metabolically directed cancer thera-
pies assumes that tumors have metabolic preferences and
vulnerabilities that distinguish them from normal tissue in vivo.
However, direct evidence for this hypothesis is scant. Warburg’s
classical experiments were performed ex vivo on tumor slices
(Koppenol et al., 2011), and the vast majority of subsequent
data was derived from cancer cell lines. These are informative
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In Vivo Analysis of Glioblastoma Metabolismapproaches, but they lack the crucial component of observing
metabolism in live tumors before separating them from their
natural microenvironment and supply of nutrients and oxygen.
13C isotopic studies are straightforward, and our data demon-
strate that important and potentially translatable information
can be produced from small tissue samples. Furthermore, there
are no barriers to generalizing this approach to other tumor
types, because a similar strategy was used to characterize
metabolism qualitatively in lung tumors (Fan et al., 2009, 2011).
Therefore we anticipate that metabolic flux studies using stable
isotopes in vivo will greatly facilitate the investigation of bona
fide tumor metabolism in mouse models of cancer and in human
patients, perhaps enabling the identification of targets for
therapy or diagnostic imaging.
EXPERIMENTAL PROCEDURES
Human Orthotopic Tumor Model
Human orthotopic tumor (HOT) samples were obtained from patients at the
University of Texas Southwestern Medical Center after written informed
consent under a protocol approved by the Institutional Review Board. The
animal portion of this study was performed under a protocol approved by
the Institutional Animal Care and Use Committee. Tumor tissue was dissoci-
ated with papain, and a suspension of 5 3 104 cells was stereotactically in-
jected into the right caudate of 6-week-old NOD/SCID mice as previously
described (Marian et al., 2010). Tumor growth was monitored using MRI (see
below) and by following the neurological status of the animals.
MRI of Mouse Brain and Tumors
MR imaging was conducted with a 7-T small animal MR system (Varian, Inc.,
Palo Alto, CA) with a 40 mm (I.D.) Horizontal Millipede Coil as previously
described (Marin-Valencia et al., 2012).
18FDG-PET Imaging
18FDG-PET imaging was performed in a small animal PET scanner with a full-
width at half-maximum resolution of 2 mm as previously described (Marin-
Valencia et al., 2012).
Infusions of 13C-Labeled Nutrients and Dissection of Brains and
Tumors
Tracer studies were initiated 8–10weeks after injection of tumor cells, when the
mice began to develop neurological symptoms (lack of grooming, cachexia,
seizures, focal deficits) according to previously published methods (Marin-
Valencia et al., 2012). Three mice (one from each tumor line) were infused with
[1,6-13C]glucose (99% enrichment; Cambridge Isotope Laboratories, Andover,
MA) and six (two from each tumor line) were infused with [U-13C]glucose (99%
enrichment; Cambridge Isotope Laboratories, Andover, MA) as follows: a bolus
of 0.4mg/gbodyweight (0.3ml)was infused in1min, followedbya continuous
infusion of 0.012 mg/g/min at 150 ml/hr for 150min. This protocol yielded a final
plasma glucose enrichment of 65 ± 15% (mean ± SD). Three mice (one from
each tumor line) were infused with [U-13C]glutamine (97%–99% enrichment;
Cambridge Isotope Laboratories, Andover, MA) as a bolus of 0.28 mg/g body
weight (0.3 ml) administered over 1 min, followed by a continuous infusion
of 0.005mg/g for 180min. This protocol yieldeda final plasmaglutamineenrich-
ment of 51 ± 13% (mean ± SD). At the end of the infusions, 100–150 ml of blood
was collected from the orbit prior to decapitation, and this plasma was used to
determine the enrichment of the relevant nutrient pool. After decapitation, the
tumors and surrounding brain tissue were rapidly dissected, weighed, frozen
in liquid nitrogen, and stored at 85C. The tumors weighed 235 ± 130 mg,
and the surrounding brain tissue weighed 406 ± 103 mg (mean ± SEM).
Metabolite Extraction
Tumors and surrounding brains were finely ground in a mortar under liquid
nitrogen and prepared for NMR analysis as previously described (Marin-
Valencia et al., 2012; Maher et al., 2012).C13C NMR Spectroscopy
Proton-decoupled 13C spectra were acquired either on a 400 MHz (Varian) or
600 MHz (Oxford) system. For the 400 MHz system, a VNMRS Direct Drive
console with a 5 mm auto-switchable broadband probe (Varian Instruments,
Palo Alto, CA) was used. Proton decoupling was performed at 2.3 kHz using
a Waltz-16 sequence. 13C NMR parameters included a 45 flip angle per tran-
sient, a relaxation delay of 1.5 s, an acquisition time of 1.5 s, and spectral width
of 24.5 kHz. Samples were spun at 20 Hz with the temperature regulated at an
ambient 25C. A 2H field-frequency lock was used. For the 600 MHz system,
a Varian VNMRS Direct Drive console using a 3 mm broadband probe (Varian
Instruments, Palo Alto, CA) was used. Proton decoupling was performed at 2.3
kHz using a Waltz-16 sequence. 13C NMR spectroscopy parameters included
a 45 flip angle per transient, a relaxation delay of 1.5 s, an acquisition time of
1.5 s, and a spectral width of 36.7 kHz. The samples were spun at 20 Hz and
25C. A heteronuclear 2H lock was used to compensate for magnet drift during
data acquisition. To achieve adequate signal-to-noise in 13C NMR spectra, the
number of scans acquired was typically 15,000. NMR spectral analysis was
performed with ACD/Spec Manager 11.0 software (Advanced Chemistry
Development, Inc., Toronto ON, Canada). Free induction decays were zero
filled and windowed with an exponential weighting function prior to Fourier
transformation. Resonances were assigned based on chemical shift position
referenced to the glutamate C4 singlet at 34.2 ppm. Each signal was fitted
with a Gauss-Lorentz function, and the area measurements for each fitted
resonance peak and the multiplet areas were estimated as previously
described (Malloy et al., 1987, 1990).
Measurement of 13C Fractional Enrichments in Blood
Blood samples were processed to measure 13C enrichment in glucose, gluta-
mine, and lactate by gas chromatography-mass spectrometry (GC-MS), as
previously described (Marin-Valencia et al., 2012). A three-point standard
curve was prepared for each metabolite by mixing unenriched glucose with
[1,6-13C2]glucose or [U-
13C6]glucose; unenriched glutamine with [U-
13C5]
glutamine; and unenriched lactate with [13C3]lactate, such that 0%, 50%, or
100% of each metabolite was 13C labeled. GC-MS was performed using an
Agilent 6890NGas Chromatograph coupled to an Agilent 5973Mass Selective
Detector (Agilent Technologies, Santa Clara, CA). One microliter of each stan-
dard or sample was injected and analyzed in scanmode. Fragment ions ofm/z
204 (unenriched) and 205 (enriched) for [1,6-13C2]-glucose; 435 (unenriched)
and 441 (enriched) for [U-13C6]-glucose; and 258 (unenriched) and 263
(enriched) for [U-13C5]glutamine were quantified for each standard and ex-
perimental sample. Linear regression was used to calculate the enrichment
of each plasma sample.
Western Blots
Fifty micrograms of whole tumor tissue extracts was used for Western
blot analysis. Primary antibodies were used according to manufacturer’s
protocols. Horseradish peroxidase-conjugated sheep anti-mouse and donkey
anti-rabbit or anti-goat secondary antibodies (Cell Signaling, Danvers, MA)
were used at 1:2000 and 1:5000 dilutions, respectively. The signal was
developedwith Super-SignalWest Pico Chemiluminescent Substrate (Thermo
Scientific, Rockford, IL).
Immunohistochemistry
Paraffin-embedded GBM specimens were obtained from the Division of
Neuropathology at UT Southwestern Medical Center. The GBM tissue and
HOT-containing mouse brains were fixed in 10% formalin and embedded in
paraffin. Sections were cut at 4 mm thickness and deparaffinized. The sections
were incubated in 3% H2O2 for 10 min to block endogenous peroxidase. The
primary antibodies and their dilutions were as follows: Neurofilament (1:2000;
2F11; M0762; Dako, Carpinteria, CA), GAD67 (Millipore, Billerica, MA), pAKT,
pERK, EGFR, (Cell Signaling, Danvers, MA). All immunostains were performed
in a Benchmark XT stainer using the CC1 pretreatment solution (95C for
32 min) and XT-UltraView Universal DAB detection system (Ventana Medical
Systems, Tucson, AZ). The sections were counterstained with hematoxylin.
GS Enzyme Assay
Fifty milligrams of tissue (tumor or brain) was homogenized by electronic
polytron in 0.5 ml of homogenization solution (0.25 M sucrose, 0.2 mMell Metabolism 15, 827–837, June 6, 2012 ª2012 Elsevier Inc. 835
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In Vivo Analysis of Glioblastoma MetabolismEDTA, 2 mM 2-mercaptoethanol). The resulting homogenate was centrifuged
at 20,000 g, 4C for 15 min. Protein concentration of the supernatant
was determined by BCA Protein Assay (Thermo Scientific, Rockford, IL).
GS activity was measured using a modification of a published method
(McDermott and Butler, 1993). Briefly, an extract containing 25–100 mg
protein was incubated with 2.5 mM L-[U-14C]glutamic acid (0.68 Ci/mol),
7.5 mM ATP, 30 mM MgCl2, 25 mM NH4Cl, and 50 mM imidazole/HCl buffer
(pH 7.5) in a volume of 250 ml. Background was determined by including a GS
inhibitor (methionine sulfoxime) in reactions with each extract. After 1 hr at
37C, the reaction was terminated by adding 1 ml of ice-cold 20 mM
imidazole/HCl buffer (pH 7.5). One milliliter of this sample was applied to a
1 ml bed volume column of AG 1-X8 anion-exchange resin (200–400 mesh,
8% crosslinked, chloride form; Bio-Rad, Hercules, CA) which had been previ-
ously equilibrated with 4 ml 20 mM imidazole/HCl (pH 7.5). 14C-glutamine
was eluted with 3 ml of the same buffer, and quantified by scintillation
counting.
Cell Culture Metabolism and Mass Isotopomer Analysis
Cells from an M-3 tumor were enzymatically disengaged and cultured in
DMEM/F12 medium supplemented with 2% (v/v) B27 serum-free supplement,
1% (v/v) insulin-transferrin supplement, 20 ng/ml epidermal growth factor,
10 ng/ml basic fibroblast growth factor, 20 ng/ml progesterone, 4 mg/ml doxy-
cycline hyclate, 0.1% Fungizone and 1% penicillin-streptomycin. Cells were
initially plated at 1 3 106 cells/dish in 10 ml of medium and grown as neuro-
spheres. When the culture reached 5 3 106 cells/dish, the spheres were
collected by centrifugation at 1000 g for 5 min at 4C. A single cell suspension
was produced by incubating the pellet in 0.5 ml of 0.25% trypsin-EDTA and
0.5 ml of 0.2% (w/v) collagenase for 10 min. This reaction was terminated by
adding 0.5 ml trypsin inhibitor (4 mg/ml). The cells were then washed once
with 10 ml PBS and replated. For 13C metabolism experiments, 1 3 106 cells
were seeded in a 6 cm dish with 4 ml of growth medium. After 2 days, the
spheres were collected by centrifugation, rinsed once in PBS and re-
suspended in 2 ml of medium containing 10 mM [U-13C]glucose for 24 hr.
Metabolites were extracted by lysing the cells in 0.5 ml of cold (20C) 50%
methanol, subjecting them to three or more freeze-thaw cycles, and centri-
fuging them to remove debris. GC/MS was used to analyze enrichment in
citrate, aspartate, malate, and glutamate. Samples were evaporated and de-
rivatized in 100 ml of a trimethylsilyl donor (Thermo Scientific, Rockford, IL),
then 3 ml were injected onto an Agilent 6890N GC coupled to an Agilent
5973 Mass Selective Detector. The retention of each metabolite was validated
using pure standards. Fragment ions of interest were monitored and quanti-
fied, and mass isotopomer distribution analysis was performed as described
previously (Cheng et al., 2011; Fernandez et al., 1996). To analyze intracellular
glutamine, we used a different approach because the GC/MS method con-
verted glutamine and other intracellular metabolites into L-pyrrolidone-
5-carboxylate, making it difficult to determine 13C enrichment in glutamine
conclusively. Extracts were evaporated and resuspended in 10 mM
tributylamine/15 mM acetic acid (pH 5.0), then filtered through a 0.2 m spin
column and injected onto a Shimadzu Prominence LC20/SIL-20AC high-
performance liquid chromatograph coupled to an AB SCIEX 3200 QTRAP
triple quadrupole mass spectrometer. Metabolites were separated chromato-
graphically on a C18-based column with polar embedded groups (Synergi
Fusion, 1503 2.0 mm 4 m, Phenomenex, Torrance, CA) using a tributylammo-
nium acetate/methanol gradient and subjected to MS/MS analysis based on
published methods (Luo et al., 2007; Tu et al., 2007). The flow rate was
0.5 ml/min using the following method: Buffer A, 10mM tributylamine adjusted
with 15 mM acetic acid to pH 5.0; Buffer B, 100% methanol. T = 0 min, 0% B;
T = 2min, 0%B; T = 13min, 100%B; T = 15min, 100%B; T = 16min, 0%B, T =
20 min, 0% B; T = 20.1 min, stop. The two best MRM transitions in negative
mode for glutamine were 145/127 and 145/109 as identified through quantita-
tive optimization. Glutamine standards were injected to confirm MRM transi-
tions and elution time. From analysis of yeast grown in 13C glucose, the
127 and 109 MS/MS daughter fragments of glutamine each contained all
5 carbons. Thus, the MRM transitions used to quantitate 13C-labeled forms
of glutamine were (m+1): 146/128, 146/110; (m+2): 147/129, 147/111; (m+3):
148/130, 148/112; (m+4): 149/131, 149/113; (m+5): 150/132, 150/114. Peaks
were quantitated and normalized against the total ion count using Analyst
1.4 software.836 Cell Metabolism 15, 827–837, June 6, 2012 ª2012 Elsevier Inc.Statistical Analysis
For NMR and IHC experiments (Figures 4D, 4G, S3E, and S3F), error bars
correspond to the SEM. In all other experiments, error bars correspond to
the SD. For data sets involving SD, statistical significance was determined
using Student’s t test (two-tailed, equal variance). Other data sets used either
the Wilcoxon signed rank test (Figure 4D) or the one-way ANOVA with
Dunnett’s post hoc test (Figure 4G).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures, including an overview of the 13C NMR approach, and
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